Veteran Operations Leader to Oversee Ankura's Global Operations and Strengthen Firmwide Performance

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Ankura Consulting Group, LLC ("Ankura"), a leading global consulting and expert advisory firm, today announced that Joanne Taylor has joined the firm as Chief Operating Officer. In the role, Taylor will lead the firm's global operations and oversee how Ankura runs day to day, sharpening performance and profitability, and building the operational foundation to help the firm scale efficiently.

Taylor brings more than 25 years of experience advising boards, private equity sponsors, and executive teams, with deep expertise in business transformation, operating-model design, and operational excellence. At Ankura, she will work to bring the firm's businesses closer together, broaden the use of AI across its operating functions, and instill the consistency and rigor that enable teams to deliver to a high standard in every market and service line.

"Joanne is a proven operational leader with a track record of building the infrastructure and discipline that enable firms to scale," said Kevin Lavin, CEO of Ankura. "As we enter our next phase of growth, her ability to align our operating model and strengthen enterprise performance will elevate how we run the firm and deliver for our clients."

Prior to joining Ankura, Taylor held senior leadership and general management roles across global consulting, technology, and services organizations, where she led complex, enterprise-wide transformations and large-scale operational turnarounds. Her leadership has been recognized by Consulting Magazine's Women Leaders in Technology, which named her Mentor of the Year. Taylor holds an MBA from Baylor University's Hankamer School of Business and is a graduate of the Harvard Leadership Consortium and the Wharton Executive Education Program.

"I'm honored to join Ankura at such a pivotal moment," said Taylor. "I look forward to working with the executive team to strengthen how the firm operates, connect our businesses, and build the modern, technology- and data-driven corporate services that will help Ankura scale with discipline."

About Ankura

Ankura Consulting Group, LLC ("Ankura") is a leading global consulting and expert advisory firm that partners with organizations at critical inflection points. Driven by its mission — Driving Excellence, Delivered with Humanity™ — Ankura delivers end-to-end solutions across conflict, crisis, performance, risk, strategy, and transformation by combining the judgment of seasoned, multidisciplinary experts with advanced technology and analytics. With more than 2,000 professionals serving 3,000+ clients around the world, Ankura brings deep industry insight, collaborative problem-solving, and innovative tools to help clients protect, create, and recover value. For more information, please visit ankura.com.

Media Contact

Carolyn Hughes

Senior Managing Director, Marketing & Communications, Ankura Consulting Group

[email protected] | 646-291-8584

SOURCE Ankura

Share this article

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating WaFd, Inc. (NASDAQ: WAFD) related to its merger with EverBank Financial Corp. Upon closing of the proposed transaction, WaFd shareholders will own approximately 40.825% of the combined company. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/wafd-inc/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

- Do you file class actions and go to Court?

- When was the last time you recovered money for shareholders?

- What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:

Juan Monteverde, Esq.

MONTEVERDE & ASSOCIATES PC

The Empire State Building

350 Fifth Ave. Suite 4740

New York, NY 10118

United States of America

[email protected]

Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

Share this article

DELRAY BEACH, Fla., Sept. 8, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Medical Supplies Market is projected to reach USD 248.03 billion by 2031 from USD 194.76 billion in 2026, at a CAGR of 7.39% during the forecast period.

Browse 450 market data Tables and 150 Figures spread through 300 Pages and in-depth TOC on "Medical Supplies Market - Global Forecast to 2031"

Medical Supplies Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 194.76 billion

- 2031 Projected Market Size: USD 248.03 billion

- CAGR (2026–2031): 7.39%

Medical Supplies Market Trends & Insights:

- Asia Pacific is expected to register the highest CAGR of 10.2% during the forecast period.

- By type, the infusion & injectable supplies segment will grow at the highest CAGR of 9.0% during the forecast period.

- By end user, hospitals led the medical supplies market, driven by rising patient admissions and increasing demand for continuous medical and surgical care.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

The global medical supplies market is growing steadily, driven by the rising prevalence of chronic and infectious diseases, rising healthcare spending, and expanding healthcare infrastructure. Growing demand for timely diagnosis, treatment, infection prevention, and surgical care is driving adoption of medical supplies across hospitals, clinics, physician offices, and other healthcare settings. The market includes a wide range of products, including blood collection consumables, dialysis consumables, wound care products, radiology consumables, disinfectants, infusion and injectable supplies, personal protective equipment, sterilization consumables, catheters, sleep apnea supplies, and surgical supplies. Rising diagnostic testing, surgical procedures, dialysis treatments, and infection-control requirements are further fueling market demand.

Diagnostic Supplies Led the Medical Supplies Market by Type in 2025 and Are Expected to Register the Fastest Growth During the Forecast Period.

The medical supplies market, by type, is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion & injectable supplies, intubation & ventilation supplies, personal protective equipment, sterilization consumables, catheters, sleep apnea supplies, surgical supplies, and other medical supplies. Among these, diagnostic supplies accounted for the largest market share in 2025 and are projected to grow fastest over the forecast period. The segment's leading position is primarily attributed to the growing need for timely and accurate disease diagnosis, the increasing burden of chronic and infectious diseases, and the expanding use of diagnostic testing across hospitals, diagnostic laboratories, ambulatory care centers, and home healthcare settings. The expansion of preventive healthcare and routine screening initiatives, along with rising healthcare expenditure and investments in diagnostic infrastructure, is further strengthening demand for diagnostic supplies.

Hospitals to Remain the Dominant End User in the Medical Supplies Market.

The medical supplies market is segmented by end user into hospitals, clinics/physician offices, and other healthcare facilities. Among these segments, hospitals hold the largest market share and are expected to retain their leading position throughout the forecast period. This dominance stems from the high volume of medical procedures performed in hospitals and the consistent need for a broad range of supplies, including diagnostic products, wound care materials, infusion products, catheters, surgical supplies, personal protective equipment, and sterilization products. The growing number of hospital admissions, along with the rising incidence of chronic and infectious diseases, is increasing demand for specialized and critical care services. Furthermore, investments in hospital infrastructure, adoption of advanced healthcare technologies, and greater emphasis on infection prevention and patient safety are driving higher consumption of disposable and sterile medical supplies. The ongoing expansion of hospitals, particularly across emerging markets, is expected to further strengthen the hospital segment's position and support its continued leadership in the global medical supplies market. 2025.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64344238

North America Dominates the Medical Supplies Market as Asia Pacific Emerges as the Fastest-growing Region.

The global medical supplies market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South America. North America held the largest market share, accounting for 40.75% in 2025. This leadership is supported by the region's well-developed healthcare infrastructure, high healthcare spending, extensive hospital networks, and strong demand for medical supplies across various healthcare settings. The region's high volume of surgical procedures, rising burden of chronic diseases, strict infection-control standards, and growing adoption of advanced medical technologies are further driving market expansion. In addition, the presence of leading medical supply manufacturers and continued investment in healthcare infrastructure are expected to help North America retain its dominant position throughout the forecast period.

Key Players

Leading players in the Medical Supplies companies include Medtronic (Ireland), Cardinal Health (US), Becton, Dickinson and Company (US), Johnson & Johnson Private Limited (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US), Thermo Fisher Scientific Inc. (US), Baxter (US), 3M (US), Smith & Nephew (UK), Convatec Inc. (UK), Abbott (US), Merit Medical Systems (US), Stryker (US), Terumo Corporation (Japan), Teleflex Incorporated (US), Fresenius Medical Care AG & Co. KGaA (Germany), Coloplast Group (Denmark), Cook Medical (US), Hamilton Medical (Switzerland), Medline Industries, LP (US), DeRoyal Industries, Inc. (US), Kerecis (Iceland), and Shenzhen MedRena Biotech Co., Ltd. (China).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Medical Supplies Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The medical supplies market is seeing increased investment activity, driven by demand for specialized devices, home healthcare, diagnostics, and chronic-disease management. Funding is increasingly focused on scalable, technology-enabled, and recurring-revenue businesses, with strong investor interest in diabetes care, surgical products, medical devices, and home medical equipment. Overall, the funding environment is shifting toward higher-growth, specialized healthcare solutions rather than commoditized supplies.

Revenue Shift Context

The medical supplies market is shifting from traditional, commodity-oriented products toward higher-value, specialized, and technology-enabled healthcare solutions. The global medical supplies market was valued at approximately USD 185.88 billion in 2025 and is projected to reach USD 248.03 billion by 2031, representing a 7.39% CAGR. Much of this growth is driven by rising demand for diagnostic supplies, infusion and injectable products, advanced wound care, infection-control products, surgical disposables, and home-care supplies.

Mergers and Acquisitions

Mergers and acquisitions in the medical supplies market in 2025 reflected ongoing consolidation across homecare, diabetes management, medical equipment, and specialized distribution. Buyers are increasingly targeting businesses with recurring patient demand, specialized products, and access to faster-growing home-based care channels. Notable transactions included Henry Schein's acquisition of Acentus, Staple Street Capital's acquisition of Avante Health Solutions, Cardinal Health's USD 1.1 billion acquisition of Advanced Diabetes Supply Group, and Sumitomo Corporation's acquisition of ActivStyle.

MEDICAL SUPPLIES MARKET: MERGERS AND ACQUISITIONS, JANUARY 2025–JUNE 2025

Company Revenue Share Details

The top five players hold 15.72% of the market, indicating a fragmented market. This level of fragmentation shows that no single vendor has established dominant control, leaving significant room for competition and consolidation in the years ahead. The top 10 key players, together accounting for about 26.27% of the total market share, are Palo Alto Networks, Fortinet, Cisco, Microsoft, IBM, Accenture, Google, Oracle, CrowdStrike, and Gen Digital. The presence of established IT giants such as Microsoft, Cisco, IBM, Google, and Oracle, alongside specialized cybersecurity vendors such as Palo Alto Networks, Fortinet, and CrowdStrike, reflects the market's broadening scope and suggests that future consolidation could come from either direction.

Browse Adjacent Market: Medical Devices Market Research Reports &Consulting

See More Latest Medical Devices Reports:

Infection Control Market by Product (Sterilization Equipment: Hydrogen Peroxide, Ethylene, Radiation), Service (ETO, Gamma, E-Beam), Disinfection (Wipes, Disinfector), Gown, Mask, Endoscope Reprocessing, End User (Hospital, Pharma) - Global Forecast to 2030

Disposable Medical Device Market by Device (Drug Delivery Devices, Surgical & Procedural Instruments, Personal Protective Equipment, Catheters & Tubes), Device Class (I, II, III), Material (Plastic-based, Metal-based, Rubber-based), and Application - Global Forecast to 2030

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space.

Former SDNY Bankruptcy Judge Robert E. Gerber Joins Zaiger Linden Roberti & Pepe

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Zaiger Linden Roberti & Pepe LLC (ZLRP), a commercial litigation boutique focused on high-stakes disputes, announced today that Hon. Robert E. Gerber, retired United States Bankruptcy Judge for the Southern District of New York, has joined the firm as Of Counsel.

Judge Gerber brings the experience of having presided over many of the nation's largest and most consequential business bankruptcies. His work at ZLRP will focus on mediation, arbitration, consulting, and fiduciary services in complex insolvency and corporate governance matters, and in litigation in those matters and others.

"We are delighted to welcome Judge Gerber to the firm," said Co-Founding Partner Jeffrey H. Zaiger. "His depth of judgment and command of complex restructuring and governance issues will meaningfully strengthen our ability to advise, litigate, and resolve our clients' most difficult disputes."

"Judge Gerber's wisdom and experience are tremendous assets," added Co-Founding Partner Douglas J. Pepe. "I have known Judge Gerber for 27 years and have missed having the ability to consult with him on complex bankruptcy issues from our days together at Joseph Hage Aaronson. I am genuinely thrilled to work with him again."

"I'm excited to join my old friends and new colleagues at ZLRP," Judge Gerber said. "The firm's quality, commitment, and culture are an excellent fit for my complex restructuring advisory, litigation, and dispute resolution work."

Judge Gerber was appointed to the bankruptcy bench in 2000, reappointed in 2014, and served on recall status beginning in 2015. During his judicial tenure he presided over a series of landmark Chapter 11 cases, including Global Crossing, Adelphia, Ames Department Stores, PSINet, ABIZ, Basis Yield Alpha Fund, BearingPoint, DBSD North America, Chemtura, Pinnacle Airlines, Houghton-Mifflin Harcourt, Lyondell Chemical, and General Motors. He handled ten cases with more than $1 billion in debt—and many others exceeding $100 million—and issued approximately 200 published opinions, focused principally on complex bankruptcy and corporate governance questions. Evaluations in the Almanac of the Federal Judiciary described him as "extremely smart," "scholarly," and "a real thinker," with "a caseload carrying a collective price tag of over $1 trillion."

Judge Gerber joins ZLRP from Joseph Hage Aaronson, where he was Of Counsel for a decade after leaving the bench, working alongside then-partners Douglas Pepe and Jeffrey Zaiger and the late Gregory P. Joseph. Before his judicial appointment, Judge Gerber was a litigation and then bankruptcy partner at Fried, Frank, Harris, Shriver & Jacobson, concentrating on securities and commercial litigation, bankruptcy litigation, and counseling. He served in the United States Air Force from 1971 to 1972, as a First Lieutenant, working in military procurement and production and, thereafter, legal assistance to service members and their families.

Judge Gerber continues as an Adjunct Professor of Law at Columbia Law School, where he has taught the Advanced Bankruptcy Seminar since 2012. He is a contributing author to Collier on Bankruptcy and a Fellow of the American College of Bankruptcy. He earned his J.D. magna cum laude from Columbia Law School, and a B.S. with high honors from Rutgers University's College of Engineering.

Judge Gerber is a member of the bars of New York and Connecticut. Though his practice will be a national (and international) one, he will be principally based in ZLRP's office in Stamford, Connecticut. He can be reached at [email protected].

His full biographical details can be found on the firm's website at https://www.zlrp.com.

SOURCE Zager Linden Roberti and Peppe, LLC

Share this article

Unlike conventional inspection systems that only detect defects after dispensing, GlassMaster Tracker continuously tracks parts during adhesive application and automatically adjusts the robot path in real time.

By tracking part-to-part variation and automatically compensating for differences in glass shape and battery-cover geometry, the system reduces process variation, minimizes production downtime caused by robot reprogramming, improves product quality and helps prevent leaks and costly rework.

Dwight Carlson, Coherix chairman and CEO, notes that the company's GlassMaster Tracker has eliminated up to five hours of weekly assembly line downtime for several customers with estimated cost savings of $22,500 per week.

Improperly installed windshields or poorly sealed battery covers present serious safety risks. A securely bonded windshield provides up to 60 percent of a vehicle cabin's structural strength, helping prevent roof collapse during a rollover accident. Inadequate battery-pack sealing can lead to moisture intrusion, battery failure and, in extreme cases, vehicle fires.

The Coherix 3D GlassMaster Tracker AI-based inspection system automatically adjusts the dispensing robot path to compensate for variations in part geometry, adhesive material viscosity and other manufacturing conditions, nearly eliminating scrap, minimizing damage to adhesive dispensing equipment and maximizing production uptime.

"No other adhesive process control system available today is capable of tracking and automatically compensating for variations in glass shape or battery-cover geometry during the dispensing process," Carlson points out. "GlassMaster Tracker is also the first solution to provide 100 percent inline real time inspection with full part traceability, giving OEMs confidence that every safety-critical bond has been properly applied."

The Coherix system records and verifies the dispensing process for every part produced, creating a permanent digital record that confirms adhesives were applied as specified. This complete traceability supports quality audits, warranty investigations and regulatory compliance while providing manufacturers with documented proof that every windshield and battery assembly meets process requirements.

With over 6,000 systems installed since its introduction in 2015, Coherix 3D has inspected millions of customer parts worldwide. The company's adaptive process control platform represents an investment of more than $100 million and more than 1,000,000 engineering hours, delivering proven technology that helps manufacturers improve quality, increase throughput and reduce manufacturing costs across a wide range of adhesive dispensing applications.

About Coherix

Coherix is a rapidly growing high-tech company that has pioneered the development of industry-first adhesive dispensing adaptive process control software technology for use in automotive, electronics and other industries.

Headquartered in Ann Arbor, Michigan, Coherix has operations in China, Germany, Japan, Mexico and Singapore.

The company's global customer base includes more than 50 of the world's leading automotive OEMs and more than 75 Tier One suppliers, including BYD, Ford, Geely, General Motors, Honda, Hyundai, Mercedes-Benz, Renault, Seres and Toyota, as well as Bosch, Gestamp, Kirchhoff, Kubota and Magna.

Major Coherix channel partners include dispensing equipment makers Graco, Nordson, Durr and Sames; robot manufacturers FANUC, Kawasaki Robotics, Yamaha Robotics, KUKA, ABB, Yaskawa, and system integrators Fives, Mino, Comau, JR Automation, Edgewater Automation and FFT.

More information is available at www.coherix.com.

SOURCE Coherix

Share this article

After tens of thousands of breast implant operations, Yale-trained San Antonio plastic surgeon Dr. Gary Lawton explains why complex revision requires reconstructive diagnosis before the first incision

SAN ANTONIO, Sept. 8, 2026 /PRNewswire/ -- Choosing the right surgeon can determine whether a complex breast implant revision produces a durable correction or another failed result. Breast implant revision is sometimes presented as a straightforward exchange of one implant for another. In reality, complex breast implant revision surgery in San Antonio may require the surgeon to diagnose and reconstruct an anatomical system altered by previous surgery, scar formation, implant forces, tissue stretching and time.

Dr. Gary Lawton, a Yale-trained plastic surgeon certified by the American Board of Plastic Surgery, has performed tens of thousands of breast implant operations during more than 25 years of independent practice. That extensive experience with both primary breast augmentation in San Antonio and complicated secondary surgery has led him to a central conclusion: a breast implant revision succeeds or fails largely according to whether the surgeon reconstructs the history and mechanics of the original operation before beginning the revision.

Primary augmentation experience is especially important because it teaches the surgeon how normal anatomy responds to implant dimensions, incision sites, pocket positions and operative techniques. Dr. Lawton treats patients whose original operations were performed through all different incisions, tissue planes and techniques.

"A revision surgeon should be able to reconstruct the original operation before making the first incision," Dr. Lawton said. "The breast tells you what happened. The scars, fold position, direction of implant displacement, animation pattern, tissue thickness, capsule and relationship between the implant and muscle are all evidence. If the surgeon cannot reverse-engineer why the first operation failed, simply repeating or modifying it is unlikely to provide a durable correction."

Revision Is Reconstructive Surgery

A primary breast augmentation begins with relatively undisturbed anatomy. A revision begins with anatomy that has already been surgically changed. The surgeon may encounter a pocket that is too large or displaced; an implant above, below or partly beneath the muscle; a shortened, divided or retracted pectoralis; capsular contracture or calcification; thin or stretched tissue; a damaged inframammary fold; implant rupture; blood-supply concerns from previous incisions or mastopexy; and overlapping planes created by multiple operations.

These conditions frequently coexist. An implant may appear too low because the fold was overreleased, the pocket stretched, the implant was too heavy for the tissue envelope, or the muscle was inadequately controlled. Each mechanism can produce a similar external appearance but require a different reconstruction.

"Revision surgery is not a procedure name," Dr. Lawton said. "It is an anatomical investigation. The surgeon must identify every layer of the failure and determine which structures can be preserved, which must be released, which require reinforcement and which must be reconstructed."

Why Extensive Primary Augmentation Experience Matters

Tens of thousands of primary breast augmentations create a depth of pattern recognition that cannot be acquired from occasional implant surgery. Repeated experience reveals how chest-wall shape changes apparent implant position; how breast-base width limits implant selection; how diameter, projection and weight interact with the tissue envelope; how the pectoralis affects movement and upper-pole contour; and how the inframammary fold responds to release, pressure and time.

It also teaches how minor preoperative asymmetries may become more visible after augmentation, how pocket dimensions determine stability and how dissection influences bleeding, inflammation, recovery and scar formation. Those lessons matter years later because early operative decisions determine which revision options remain available.

"Every primary augmentation is also a long-term lesson in revision prevention," Dr. Lawton said. "When you have performed breast augmentation across an enormous range of anatomies, implant dimensions and tissue characteristics, you develop an internal reference library. That experience allows you to recognize not only what is wrong during a revision, but what the anatomy should have looked like before it was altered."

Seven Reasons Breast Implant Revisions Go Wrong

1. The Visible Deformity Is Mistaken for the Diagnosis

Bottoming out, lateral displacement, symmastia, high implant position, double-bubble deformity and animation describe appearance; they are not complete diagnoses. The surgeon must determine whether the cause is incorrect pocket creation, progressive stretching, fold disruption, muscle malposition, capsular contracture, implant mismatch, tissue weakness, previous overcorrection or several interacting problems. Treating appearance without identifying mechanism invites recurrence.

2. The Implant Is Exchanged Without Reconstructing the Pocket

Removing one implant and inserting another does not correct a defective implant pocket. An enlarged pocket may require precise internal closure. A scarred or distorted pocket may require targeted release. A displaced fold may require reconstruction, while a compromised plane may need conversion or replacement with a new pocket.

"The implant occupies the space the surgeon creates or inherits," Dr. Lawton said. "If that space is mechanically wrong, changing the implant alone does not correct the operation."

3. The Capsule Is Treated as a Single Problem

The capsule is the patient's scar tissue surrounding the implant, and its thickness, vascularity, adherence and mechanical behavior can vary throughout the breast. One region may need selective release, another internal closure, another excision of pathologic tissue and another preservation of useful capsule. Complete capsulectomy is not automatically required for every revision, just as simple capsulotomy is not sufficient for every contracture. Treatment must follow the pathology, implant condition, tissue quality, pocket mechanics and reconstructive objective.

4. The Pectoralis Muscle Is Misunderstood

In submuscular and dual-plane augmentation, the pectoralis is part of both the implant-support system and the visible result. Previous surgery may leave it incompletely or excessively released, scarred to the capsule, retracted superiorly, displaced or exerting asymmetric force. A pocket can appear acceptable while the patient is motionless yet distort when she contracts her chest. The revision surgeon must understand the muscle dynamically to prevent recurrent displacement or persistent animation.

5. Implant Dimensions Are Not Matched to the Reconstruction

Implant volume alone does not define implant behavior. Width, projection, profile, weight and shell characteristics determine the forces applied to the reconstructed pocket and surrounding tissue. Even a technically repaired pocket can fail if the replacement implant exceeds the breast-base width, overloads weak lower-pole tissue, produces excessive lateral pressure, requires unstable expansion or is incompatible with the remaining coverage. The implant must fit the reconstructed anatomy, not merely a requested cup size.

6. Tissue Deficiency Is Ignored

Repeated operations can leave thin skin, attenuated breast tissue, damaged fascia, internal scarring and compromised blood supply. Some revisions fail because the plan expects weakened tissue to provide normal support. Responsible reconstruction may require a smaller or lighter implant, different dimensions, pocket repair, tissue preservation or rearrangement, added internal support, staged correction or a decision not to operate. The most aggressive procedure is not necessarily the most reconstructive.

7. The Breast Is Not Reassessed as a Three-Dimensional System

Revision cannot be judged solely with the patient lying flat. Intraoperative assessment should examine implant height and symmetry, fold position, medial and lateral boundaries, upper- and lower-pole relationships, implant behavior inside the reconstructed pocket and breast shape with the patient seated. It also must account for the interaction of implant, muscle, capsule, skin and breast tissue. Small pocket errors can become significant deformities after healing and months of implant pressure, especially when previously operated tissues have little remaining tolerance for error.

Experience Is More Than Repetition

Revision may be required for recurrent ptosis, capsular contracture, malposition, rippling, rupture or implant-size changes. Safe reconstruction requires a plan for nipple-areola blood supply, implant plane and dimensions, capsule management, incision selection, tissue quality and patient-related risk factors. This is why complex revision should be undertaken by a plastic surgeon with substantial reconstructive revision experience and an extensive foundation in primary augmentation—not by a surgeon who performs implant surgery only occasionally.

"Experience is not simply the number of years since training," Dr. Lawton said. "It is the cumulative ability to recognize patterns, anticipate tissue behavior, understand the consequences of previous decisions and formulate the reconstruction before the operation begins."

Primary augmentation experience teaches how implant anatomy is created. Revision experience teaches how that anatomy fails and how it can be rebuilt. The two forms of experience are inseparable when the objective is a durable reconstruction rather than another temporary implant exchange.

The First Operation Determines the Revision

The best opportunity to prevent breast implant revision occurs during the primary augmentation.

U.S. Last-Mile Leaders Win on Control, Not Speed, FarEye Research Finds

High-control operators achieve 95% on-time performance; speed-first operators report 24% median cost inflation

CHICAGO, Sept. 8, 2026 /PRNewswire/ -- U.S. delivery operators are entering a phase where control and predictability are emerging as stronger performance differentiators than speed, according to FarEye research.

Eye on the Last Mile America 2026 draws on more than 500 U.S. delivery operators and over 3,000 data points. It finds median year-over-year cost per delivery increased 12% in 2026, while 88% say delivery costs are growing at the same pace as revenue or faster.

"The last mile is fundamentally about control. As supply chains become more distributed across carriers, couriers and gig providers, companies need to orchestrate the network as one. Technology, carriers and processes matter, but when something changes, the ability to connect everything and respond quickly ultimately determines the customer experience. That's what stood out in FarEye's findings and my conversations with industry leaders at the conference."

- Nick Costides, C-Level Advisory, Former Global President of IT, UPS

The research identifies a 'speed penalty.' Operators prioritizing the fastest possible delivery report 76% on-time performance and 24% median cost inflation. In contrast, high-control operators achieve 95% on-time performance, compared with 65.5% among low-control operators, despite both groups reporting the same median investment level.

"The last mile is becoming a test of orchestration, not investment. The companies that get this right won't just deliver better — they'll grow without their cost base growing with them," said Kushal Nahata, CEO & Co-Founder, FarEye.

The report was unveiled at Last Mile Leaders America 2026, held August 26–28 at The Gwen in Chicago. Read the report: REPORT LINK

The findings also show that 55.7% of operators prioritize predictable delivery or first-attempt success, compared with 11.4% prioritizing the fastest possible delivery.

About FarEye

FarEye is an AI-Powered Delivery Management System (DMS) for the last mile & order-to-door logistics. FarEye is a partner for companies obsessed with a superior delivery experience for their customers, while driving efficiency gains, sustainably with smarter delivery orchestration.

Our vision is to ensure every delivery in the world reaches its destination every time, on time, accurately, efficiently, and as sustainably as possible.

FarEye has 150+ customers across 30 countries and seven offices globally.

FarEye, First Choice for Last Mile.

SOURCE FarEye Technologies Pvt. Ltd

Share this article

The sarcoidosis market is expected to experience steady growth over the coming years, supported by increasing disease awareness, improvements in diagnosis, and the growing need for effective long-term treatment options. Additionally, the launch of emerging therapies such as KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), and others will further propel the market growth.

LAS VEGAS, Sept. 8, 2026 /PRNewswire/ -- Recently published Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment practices, sarcoidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Sarcoidosis Market Summary

- The total sarcoidosis treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest sarcoidosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- Sarcoidosis is a rare disease, with an estimated 150,000–200,000 cases in the US each year and approximately 27,000 new cases diagnosed annually.

- Leading sarcoidosis companies, such as Kyorin Pharmaceutical, aTyr Pharma, Priovant Therapeutics, Molecure, Xentria, OrphAI Therapeutics, Quince Therapeutics, MindMaze Therapeutics, Foresee Pharmaceuticals, and others, are developing new sarcoidosis treatment drugs that can be available in the sarcoidosis market in the coming years.

- The promising sarcoidosis therapies in clinical trials include KRP-R120 (Efzofitimod), Brepocitinib, OATD-01, XTMAB-16, LAM-001, RLF-100, Aderamastat (FP-025), and others.

Discover latest insights on sarcoidosis therapeutics market @ https://www.delveinsight.com/report-store/sarcoidosis-market

Key Factors Driving the Growth of the Sarcoidosis Market

- Growing Prevalence of Sarcoidosis: An increasing number of diagnosed cases across major markets is expanding the addressable patient population. Improved disease surveillance and recognition of extrapulmonary manifestations are further contributing to higher diagnosis rates.

- Limitations of Existing Treatments: Corticosteroids remain a cornerstone of treatment, but their prolonged use can result in significant adverse effects. Concerns over steroid-related toxicity and inadequate responses in some patients are driving demand for alternative and steroid-sparing therapies.

- Expansion of Targeted and Biologic Therapies: Growing understanding of the immune pathways involved in sarcoidosis is accelerating the development of targeted treatments, including biologics and other immune-modulating therapies. These approaches could provide more effective disease control for patients with refractory disease.

- Growing Clinical Development Activity: Increasing investment from biotechnology and pharmaceutical companies has led to a more robust pipeline of sarcoidosis therapies including KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), LAM-001 (OrphAI Therapeutics/Quince Therapeutics), RLF-100 (MindMaze Therapeutics), Aderamastat (FP-025; Foresee Pharmaceuticals), and others. Multiple late-stage and mid-stage clinical programs are expected to generate important data over the coming years, supporting market expansion.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, efzofitimod is expected to achieve significant uptake following potential approval, supported by its novel immunomodulatory mechanism and ability to reduce corticosteroid dependence while preserving disease control. Its differentiated mechanism and favorable safety profile could position it as an attractive option for patients with chronic pulmonary sarcoidosis.

Sarcoidosis Market Analysis

- The treatment landscape for sarcoidosis has progressed incrementally over the years; however, substantial unmet needs persist because of the limited number of therapies specifically developed for the disease.

- At present, Acthar Gel (repository corticotropin injection) remains the only FDA-approved treatment specifically indicated for symptomatic pulmonary sarcoidosis.

- Although corticosteroids and immunosuppressive therapies remain the cornerstone of management, their long-term use is associated with safety concerns, inconsistent treatment responses, and the risk of disease recurrence. These limitations have accelerated efforts to develop more targeted and disease-specific treatment strategies.

- Among the emerging therapies, efzofitimod has attracted significant attention because of its novel immunomodulatory mechanism and potential to reduce reliance on corticosteroids in patients with pulmonary sarcoidosis.

- Brepocitinib has shown promising clinical activity in cutaneous sarcoidosis and could provide a targeted option for addressing chronic inflammatory pathways implicated in disease progression.

- OATD-01 is evaluating a potentially first-in-class chitinase inhibition approach designed to influence granulomatous inflammation and fibrotic processes, while XTMAB-16 has progressed into mid-stage clinical development, with topline results anticipated to provide further insights into its therapeutic value.

- Collectively, these pipeline therapies employ diverse mechanisms of action and could broaden the treatment landscape beyond traditional immunosuppressive approaches.

- Overall, the sarcoidosis market across the 7MM is projected to expand steadily through 2036, driven by improvements in disease diagnosis and the increasing development of targeted treatment candidates.

- As these therapies advance through clinical development, agents offering steroid-sparing effects, enhanced safety, and potential disease-modifying benefits could substantially transform the treatment paradigm.

- This evolving pipeline may also unlock significant commercial opportunities within a market that currently has a relatively limited range of approved disease-specific treatment options.

Sarcoidosis Competitive Landscape

Some of the sarcoidosis drugs under development include KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), LAM-001 (OrphAI Therapeutics/Quince Therapeutics), RLF-100 (MindMaze Therapeutics), Aderamastat (FP-025; Foresee Pharmaceuticals), and others.

Kyorin Pharmaceutical and aTyr Pharma's Efzofitimod is an innovative biologic immunomodulator under clinical development for interstitial lung disease (ILD), a group of immune-mediated conditions characterized by lung inflammation and fibrosis, or permanent scarring. Derived from a tRNA synthetase, efzofitimod selectively targets activated myeloid cells through neuropilin-2, with the aim of resolving inflammation without causing broad immune suppression and potentially slowing or preventing fibrotic disease progression.

The therapy is currently being evaluated in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, also known as scleroderma)-associated ILD. In addition, aTyr has submitted a protocol to the FDA for a global Phase 3 trial evaluating efzofitimod in pulmonary sarcoidosis, a significant form of ILD. Given the limited treatment options available for these ILD subtypes, there remains a significant need for safer, more effective disease-modifying therapies that can improve patient outcomes.

The US FDA has granted Orphan Drug Designation (ODD) to efzofitimod for the treatment of sarcoidosis, along with Fast Track Designation (FTD) for pulmonary sarcoidosis. In Europe, the European Commission has awarded efzofitimod Orphan Drug Designation for sarcoidosis following a positive recommendation from the EMA's Committee for Orphan Medicinal Products (COMP). In Japan, the Pharmaceutical and Medical Devices Agency (PMDA) has granted Kyorin Pharmaceutical Orphan Drug Designation for efzofitimod in the treatment of sarcoidosis.

Priovant Therapeutics' Brepocitinib is an investigational oral dual TYK2/JAK1 inhibitor being developed for a range of autoimmune and inflammatory conditions, including cutaneous sarcoidosis. The therapy was assessed in the Phase 2 BEACON trial, a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of oral brepocitinib in adults with cutaneous sarcoidosis. Following encouraging results from the Phase 2 BEACON study, Priovant intends to initiate a Phase 3 clinical trial of brepocitinib in cutaneous sarcoidosis in 2026.

The anticipated launch of these emerging therapies are poised to transform the sarcoidosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the sarcoidosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the pulmonary sarcoidosis market @ Sarcoidosis Therapeutics Clinical Trials

Recent Developments in the Sarcoidosis Market

- In July 2026, aTyr Pharma, Inc. presented a subgroup analysis from the Phase 3 EFZO-FIT™ trial evaluating efzofitimod in pulmonary sarcoidosis, a significant type of interstitial lung disease, at the 2026 Congress of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), held July 15–17, 2026, in Porto, Portugal.

- In May 2026, Xentria presented the latest update on XTMAB-16 in sarcoidosis. XTMAB-16 demonstrated a favorable safety and tolerability profile in patients with pulmonary sarcoidosis, without unexpected TNF-inhibitor class effects.

Experienced orthopedic executive to lead mission-driven business focused on restoring mobility and independence for veterans and patients facing complex limb reconstruction.

AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- OsteoCentric Technologies announced the appointment of Jeffrey S. Zanni as President and General Manager of Oncology and Limb Restoration, a business focused on oncology, complex reconstruction, limb salvage, and limb restoration prosthesis.

At the center of the business is a human problem that transcends technology: helping someone who has experienced devastating injury or limb loss regain mobility, independence, and quality of life. For OsteoCentric, that mission carries particular meaning for veterans whose service and sacrifice have resulted in life-altering physical challenges.

Zanni will lead the strategic, operational, and commercial development of the business, expanding the application of OsteoCentric technologies in some of the most clinically demanding areas of orthopedic care.

Zanni brings more than two decades of executive leadership experience across orthopedics, medical devices, biologics, advanced implant technologies, and osseointegration. He has held senior leadership roles with Stryker Orthopaedics, Tornier, Conventus Orthopedics, and Integrum, where he served as U.S. President. His background spans public company leadership, private equity-backed growth organizations, full P&L responsibility, commercial scale-up, and the launch of disruptive technologies.

"Jeff is being asked to build a business around a human problem we all immediately understand: helping someone who has sacrificed regain mobility, independence, and quality of life," said Eric Brown, CEO of OsteoCentric Technologies. "For our veterans and others facing devastating injury or limb loss, restoring mobility can mean restoring a part of the life they fought to protect. That is the mission behind this business. Jeff brings the experience, discipline, and leadership to turn that mission into meaningful impact at scale."

"Throughout my career, I have seen what restoring mobility can mean for a patient and their family," said Zanni. "This is an opportunity to pair meaningful innovation with a mission centered on restoring mobility and independence. I look forward to working with surgeons, veterans, patients, and our team to expand what is possible in limb restoration and AI bionic technology."

Zanni received a Bachelor of Arts in Law and Legal Studies from the University of Massachusetts and completed advanced Master of Public Health coursework at Boston University.

About OsteoCentric Technologies

OsteoCentric Technologies develops and commercializes UnifiMI, a platform technology designed to provide stable and durable mechanical integration across clinical and industrial applications. The company is headquartered in Austin, Texas.

SOURCE OsteoCentric Technologies

Share this article

Al Shams Expresses Intention to Nominate Majority Slate of Independent Directors for Braemar Hotels & Resorts

Braemar's Annual Meeting Announcement and Compressed Nomination Window Represent the Latest Example of Troubling Governance Practices

Releases Letter to Shareholders

PEMBROKE, Bermuda, Sept. 8, 2026 /PRNewswire/ -- Al Shams Investments Limited ("Al Shams" or "we"), the largest shareholder of Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company"), today indicated its intention to nominate a slate of directors to the Board of Braemar and released a letter to shareholders.

The full text of the letter follows:

Fellow Braemar Shareholders,

On the 4th September, Braemar Hotels & Resorts announced the date of its 2026 Annual Meeting and, with it, a September 14 deadline relating to shareholder director nominations, providing shareholders with an extraordinarily short window and choosing to make the announcement immediately before a long holiday weekend.

After everything shareholders have witnessed at Braemar, this latest maneuver is unfortunately consistent with the governance practices I have addressed in my previous letters. Announcing a compressed nomination window over a holiday weekend appears designed to keep shareholders off guard and make the process unnecessarily difficult.

If the Board believed that this timing would leave Al Shams unprepared, it was mistaken.

Al Shams Investments Limited is fully prepared and intends to nominate a complete slate of highly qualified, independent directors sufficient to constitute a change in control of the Board. Our nominations will be submitted in full compliance with the applicable requirements and within the required timeframe.

The Board should not confuse procedural gamesmanship with effective governance. Shareholders are entitled to a genuine choice regarding who represents them in the boardroom, particularly given the longstanding concerns surrounding Braemar's governance, external management structure and alignment with shareholders.

We will shortly present our five nominees who, if elected, will work tirelessly to safeguard the interests of shareholders.

Respectfully,

Al Shams Investments Limited

About Al Shams Investments Limited

Al Shams Investments Limited is a Bermuda-based private investment company focused on global investments across private equity, real estate, and alternative asset classes.

Certain Information Concerning the Participants

Al Shams, together with the other Participants (as defined below), intends to file with the U.S. Securities and Exchange Commission (the "SEC") a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying WHITE Universal Proxy Card to be used to solicit proxies from the shareholders of the Company in connection with the Annual Meeting.

SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE SEC BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE ANNUAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE.

At this time, the participants in the solicitation of proxies are anticipated to be Al Shams and Wafic Rida Said (collectively, the "Participants").

The Definitive Proxy Statement and accompanying WHITE Universal Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on July 23, 2026, and is available here. As of the date hereof, by virtue of the relationship among the Participants as members in a Schedule 13(d) group and solely for the purpose of such Schedule 13(d) group, each of the Participants is deemed to beneficially own the 6,513,000 shares of Common Stock of the Company, par value $0.01, held directly by Al Shams.

Investor and Media Contact

Karim Khatoun

Email: [email protected]

SOURCE Al Shams Investments Limited

Share this article